Ahlstrom Acquires EBF to Strengthen Life Science Portfolio

Ahlstrom Acquires EBF to Strengthen Life Science Portfolio

Source: Ahlstrom

Industry News

Ahlstrom has acquired EBF, a Greenville, South Carolina-based manufacturer specializing in natural fiber-based medical devices for biological sample collection. 

The move strengthens Ahlstrom’s position in the life science sector, particularly in the growing diagnostic testing market.

Expanding diagnostic capabilities

EBF is widely recognized as the leading provider of newborn screening devices, including 903 diagnostic cards and procedure packs. Its expertise in advanced printing, sequential numbering, and custom packaging adds valuable capabilities to Ahlstrom’s offering in specialty materials and converting solutions.

“With EBF’s high-quality business and technical know-how, we are moving forward in the value chain and expanding our expertise in card manufacturing,” said Daniele Borlatto, EVP for Filtration and Life Sciences at Ahlstrom. “This acquisition allows us to offer more comprehensive solutions and further strengthen our position in diagnostic testing.”

Strategic fit for growth

EBF will become part of Ahlstrom’s Filtration and Life Sciences business, supporting the company’s broader strategy to grow its laboratory and life sciences portfolio. By combining EBF’s expertise with Ahlstrom’s global reach, the company aims to enhance its presence in blood and urine testing, including newborn screening.

Brad Nelson, CEO of EBF, welcomed the move: “We are thrilled to join Ahlstrom, a global leader whose resources and worldwide presence will enable us to expand our product portfolio and reach new markets.”

Focused on growth in life sciences

The acquisition represents a key step in Ahlstrom’s growth strategy, reinforcing its ambition to be a leading supplier of sustainable specialty materials. In 2024, Ahlstrom reported net sales of EUR 3.0 billion and employs about 7,000 people worldwide.

Founded in 1964, EBF has decades of experience supplying specimen collection devices for newborn screening, enabling the detection of more than 20 disorders. Its facility in Greenville, South Carolina, will continue operations under Ahlstrom ownership.